SUMMARY The effects of hepatic transit on concentrations of synthetic cyclic (ovine) somatostatin and of highly purified (porcine) vasoactive intestinal peptide were studied in five conscious dogs prepared with indwelling portal catheters. The peptides were infused via peripheral vein catheters or the portal catheters for 40 minutes at actual integrated doses of 2.8 pmol/kg/min for vasoactive intestinal peptide and 8.2 pmol/kg/min for somatostatin. Specific radioimmunoassays were used for the measurement of the circulating peptides. As estimated from the plateau peptide concentrations achieved in a hindleg vein during the portal and the peripheral infusions, the transhepatic loss of immunoreactive vasoactive intestinal peptide was 72.9±2 1%, against 275 +12.5% for somatostatin. For the given doses of peptides infused systemically, the half-life, metabolic clearance rate, and distribution volume were, respectively, 1h80±0i1 minutes, 39.3± 5.2 ml/kg/min, and 1037±+14-8 ml/kg for vasoactive intestinal peptide, and 1 (0±02 minutes, 952 +12.5 ml/kg/min, and 1 14.7+6 0 ml/kg for somatostatin. These results indicate that (ovine) somatostatin and (porcine) vasoactive intestinal peptide are both readily cleared from plasma in dogs. In the present experimental conditions, vasoactive intestinal peptide, but not somatostatin, was rapidly altered through hepatic transit so that it escaped recognition by the assay system. Somatostatin, a tetradecapeptide first isolated from ovine hypothalamus,' and vasoactive intestinal peptide (VIP), an octacosapeptide characterised from porcine upper intestine,2 are two of the peptides common to the central nervous system and the digestive tract. Both are widely distributed in the gastrointestinal tract and the pancreas,3 and exogenous preparations exhibit wide spectra of biological effects.5 6 Physiological mechanisms of release and actions, however, are unclear for both.
Somatostatin, a tetradecapeptide first isolated from ovine hypothalamus,' and vasoactive intestinal peptide (VIP), an octacosapeptide characterised from porcine upper intestine,2 are two of the peptides common to the central nervous system and the digestive tract. Both are widely distributed in the gastrointestinal tract and the pancreas,3 and exogenous preparations exhibit wide spectra of biological effects.5 6 Physiological mechanisms of release and actions, however, are unclear for both.
The two peptides are considered local transmitters, either paracrine or neurocrine, although substances displaying somatostatin-and VIPimmunoreactivity have been detected in portal and peripheral plasma.7 8 The physiological importance of these circulating components is not known.
The effect of hepatic transit on VIP originating from the digestive tract remains controversial. Physiological studies have shown that the biological activity of the peptide is reduced when it is infused into the portal vein instead of the peripheral circulation,9 10 but Strunz and colleagues '" failed to confirm this apparent hepatic inactivation. The hepatic inactivation of somatostatin has not been investigated.
The present work was undertaken to study comparatively the effects of hepatic transit on (ovine) somatostatin and (porcine) VIP Half-life, metabolic clearance rate (MCR), and distribution volume (DV) were estimated from the data of systemic infusion, using as incremental plateau value the mean incremental plasma peptide concentrations at 35 and 40 minutes during infusion.
The half-life was calculated by the relation T5(0= 0.693/k, where k is the slope of the regression line between the natural logarithm of incremental plasma peptide concentration, expressed as percentage of plateau value, and time in minutes. The MCR, in ml/kg/min, was equivalent to D/P, where D is the dose of peptide in pmol/kg/min and P the incremental peptide concentration at plateau value in pmol/ml. The DV, in ml/kg, was equal to D/Pk.
The relation Ps-Pp/Ps, where Ps and Pp are the mean incremental plasma peptide concentrations achieved during systemic (Ps) and portal (Pp) infusion, was used as an index of the fraction of peptide lost through a single hepatic transit.
The plasma somatostatin concentration was measured with a radioimmunoassay previously described,'2 which was improved for determination of somatostatin in plasma by using antiserum 56D. ': This antiserum, raised against synthetic cyclic somatostatin conjugated with bovine albumin through carbodiimide condensation'2 recognises primarily the 8-11 portion of the tetradecapeptide, as checked with analogues resulting from alanine substitution in positions 4, 6, 8, and 11 (a gift from Dr J Rivier and Professor R Guillemin), which have relative potencies (ID 50) of 1.0, 0.04, 0-008 and <0(0004, respectively, as compared with the unaltered molecule. 1 -tyrosyl somatostatin (Serono) was labelled to a specific activity of 150-22() .tiCi/4g with 1251 (Amersham) using lactoperoxydase. It was purified by chromatography on a 1 x 10 cm column of carboxymethylcellulose CM 52, equilibrated and loaded in 0.05 M ammonium acetate pH 5.5 and developed with 0.5 M ammonium acetate pH 6.0. The sensitivity was 0-9-1 8 pmol/l of incubate. The within-assay (35 pairs) and between-assay (53 pairs) variations were 7 1% and 12.3%, respectively (coefficient of variation). The recovery of 2, 4, 8, and 16 pg somatostatin per tube in plasma varied from 80.4% to 98.1% (seven determinations per dose).
VIP was measured with a radioimmunoassay recently reported'3 using antiserum 76A, which shows only little reactivity towards the C-terminal portion of the porcine peptide (ID 50:0-1) and no reactivity towards the N-terminal part of the molecule (<0 0001, a gift from Professor M Bodanszky), as compared with the whole molecule (= 1 0). Highly purified porcine VIP was labelled to a specific activity of 200-300 uCi/,ug with 1251 using lactoperoxidase, and was purified on a 1 x 10 column of SP C25 Sephadex equilibrated and loaded in 0.2 M ammonium acetate (pH 5.0) and developed with 0.8 M ammonium acetate (pH 5.6) with 5% human plasma. The sensitivity was 0-5-10 pmol/l. The estimates for within-assay, between-assay variation, and recovery, tested as for somatostatin, were 7.0%, 7.2%, and 79.7% to 100.4%, respectively.
The two systems appeared to be specific against the other gastrointestinal peptides and brain peptides'2 tested at concentrations of 100 ng per tube.
Both assay systems were used simultaneously to measure VIP and somatostatin in the same sample. A standard curve in charcoal-treated plasma was generated for each dog studied. Unknown samples and peptide-free plasma were acidified to pH 5.5-6.0 with 0.4 M acetic acid before incubation. Incubation lasted for five days at 4°C in 0.05 M potassium phosphate-0.1 M sodium chloride pH 5.5, with addition of tracer after 24 hours and of second antibody (used for separation of bound and free peptide) added on the fourth day. Results were expressed as pmol/l and converted into pmol/ml for calculations. The sensitivity limit of the individual assay was taken as the actual value for samples with concentrations below the limits of detection.
Results
Systemic infusion of VIP at 5.0 pmol/kg/min (actual value as measured: 2.8 pmol/kg/min) induced an increase in peripheral plasma VIP from 4-0±0.8 pmol/l to a mean plateau value of 81.0±10.1 pmol/l. An increase from 4*5±0*8 to 25-6±3.4 pmol/l was found when the same dose was delivered into the portal vein (Fig. 1) . The estimated loss of peptide on hepatic transit was 72 9±2.1%. After the infusion was stopped, the plasma VIP concentration decreased to baseline in 14 minutes after systemic administration, and in eight minutes after portal infusion. Estimated from the results of systemic infusion, the half-life (Fig. 2) , metabolic clearance rate, and apparent volume of distribution of porcine 9 -e-VIP were calculated to be 1 80±0 1 n 5.2 ml/kg/min, and 103*7±14*8 ml/ki Systemic infusion of 10.2 pmol/1 dose as measured: 8.2 pmol/kg/min caused plasma somatostatin to incre2 6-8 to a mean plateau value of 108.6± compared with an increase with porta 18-4±6-5 at basal to 83-8±16-8 pmol apparent loss of somatostatin on hep 27-5l12-5%. At the end of the infus of plasma somatostatin after portal infusions were superimposable, a values for both returned to baseline i (Fig. 3) . Estimated from the dat infusion, the half-life (Fig. 2 ) was extrapolation to be 1-0±0-2 minutes. clearance rate was 95.2±12.5 ml/k apparent volume of distribution, 11l ninutes, 39.3± adsorption of secretin, which is structurally related g, respectively. to VIP, on plastic tubing, amounts to nearly 50% of kg/min (actual doses which were similar to those used here for VIP l) somatostatin and somatostatin,17 the adsorption of these preparaase from 15 2± tions on the infusion sets was checked in parallel :14.0 pmol/l, as control experiments. Somatostatin was only slightly fl infusion from adsorbed, while the integrated loss of VIP during a l/1 (Fig. 3) . The 40 minute infusion almost reached 50% of the initial atic transit was dose, a figure rather similar to that reported in the ion, the curves single study in which this estimation was reported. 18 1 and systemic We did not attempt to delineate the adsorption nd the mean kinetics of somatostatin and VIP on plastic tubing, in four minutes because the infusion lines were strictly replicated ta of systemic for the portal and the peripheral infusions.
calculated by However, the fact that the values of plasma the second 20 minute period. Somatostatin was apparently affected only moderately by hepatic transit (uptake or alteration of 27.5±12 5% of peptide infused through the portal system). Whether the fraction of peptide resisting hepatic transit was biologically active was not tested in the present study. However, antiserum 56D recognises a portion of the tetradecapeptide which appears to be essential for biological activity, especially the phenylalanine residue in position 8.19 Our data do not exclude a transhepatic alteration of the N-terminal portion of the tetradecapeptide, but '40"" '-' ' '56 provide circumstantial evidence for possible effects of the somatostatin originating from the digestive system on post-hepatic target organs.
1tostatin
From the present results, it appears that somato-1O2 pcmollkg/ statin (at least the ovine tetradecapeptide) is readily tC cyclic cleared from plasma in dogs, with a half-life of approximately one minute. This figure is roughly comparable with that (1-82 minutes) derived from studies in dogs by Schusdziarra and colleagues. '5 These authors recorded an increase of plasma somatostatin of about 300% above basal for an apparent n to evaluate dose of approximately 10-0-12-0 pmol/kg/min, as ransit on ovine compared with the 600% increase obtained with ministered to 10.2 pmol/kg/min in the present study. The ito induce sig-discrepancy appears to result from different somatostatin estimates for basal plasma somatostatin concentraetical rate of tions in dogs, probably because of different antioeen shown to serum specificities or assay methodologies. Half-life strin and acid values of 1. 1-3-0 minutes were recently reported in .ase of insulin man,20 with MCR values of 15-45 ml/kg/min. The ', delivered at figure obtained here and that given by Schusdziarra )mol/kg/min), and colleagues'5 in dogs suggest that somatostatin induced acid may be cleared more rapidly from plasma in dogs logs. 16 As the than in man.
In experimental conditions identical with those applied for somatostatin, the half-life of porcine VIP was close to two minutes. This figure is intermediate between those reported by Domschke and colleagues'8 in man and by Modlin and colleagues2' in anaesthetised pigs, both close to one minute, and that (about three minutes) reported by Strunz and colleagues" in dogs with portacaval transposition. As to other aspects of VIP kinetics, the present figures are different from those obtained by Modlin and colleagues21 and Domschke and colleagues.'8 Using the same VIP assay for the two studies, these groups recorded a distribution volume of VIP of less than 2% of the body weight both in man and pigs, as compared with a figure of about 10% in the present experiment. As the doses of peptides actually infused were controlled in all these studies, and as at least some of these doses were comparable, the most likely reason for this discrepancy is the difference between the plasma VIP levels achieved under infusion, which were lower in our study than in theirs. The same batch of pure VIP was used here for the in vivo infusions, and in vitro adsorption controls, and for setting up the standard curves, so that it is unlikely that the comparatively low plasma VIP levels achieved here reflected simply the administration of a spuriously low amount of peptide. Though the metabolism of porcine VIP may be different in dogs and in other species, as suggested by the fact that the half-life in dogs" was found to be three times as high as those in man'8 and 
